Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, August 27, 2026

Back to today

Late August 2026 Random Ramblings

Higher rates could compress equity multiples and raise AI data center lease costs, while UWMC and Cogent raise questions about CEO-driven capital allocation.

UWMC $2B
Yet Another Value Podcast 13 clicks

From X

@majgeoinvesting

Maj Soueidan on X

Been thinking about $FTEK for the last couple days. My first reaction to the Q2 report was disappointment (although, it was largely expected). However, I’m trying to get better at flipping my initial positive or negative emotional reactions and think of the counter responses. For FTEK, that would be: ✔️Tiny bit of information arbitrage in the earnings call that they are trying to iron out some things with a data center customer on supply chain guarantees. The key here is that they’re having active discussions with that customer. I don’t think they previously got anywhere close to that. ✔️The new CEO could potentially flip the narrative on FTEK pretty quickly. It looks like the company has a bloated expense profile. I want to see if there’s anything in that structure that could be eliminated, that would quickly make the company profitable. ✔️Furthermore, maybe the new CEO takes the company’s $30M cash balance, and makes an acquisition. Due to his experience working at $CECO prior to joining FTEK, he should have some experience evaluating acquisitions,

Investor Letters

All letters

Vidrala

Vidrala has grown from a Spanish glass-container maker into a multi-country packaging platform with expanding Latin American exposure.

VDRFF $3.6B
smallvalue. 6 clicks
CC · long

the chemours inc.

Chemours (CC) is presented as a long investment in its three-segment specialty chemicals business.

CC $2.3B
Value Investors Club

Haw Par Corporation Limited

Haw Par combines Tiger Balm’s stable cash flows with property, leisure and healthcare operations plus stakes in UOB and UOL.

HAWPY $3B
smallvalue. 4 clicks

National Beverage Update

National Beverage’s rare share repurchase is framed as a buy signal, with 50% upside projected.

FIZZ $3B
Nat Stewart - Stock Picking Newsletter 3 clicks

Tis The (Earnings) Season

Argentine banks, tariff-exposed stocks and Customer’s Bancorp anchor an earnings-season watchlist after Milei’s election victory,…

CUBI $2.7B
Cluseau Research 3 clicks

When extend and pretend is a virtue

Upstart says longer repayment terms lifted Q1 debt-settlement acceptances 50%, but does not disclose delinquency changes or the number of…

UPST $2.4B
John Hempton's Newsletter 2 clicks

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2.2B
John Hempton's Newsletter 1 click

Publications we follow

Every publication on this site, hand-picked.

108 publications

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 29 of 158

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

68 accounts
Nominate an account

Investor letters we follow

78 firms

Sectors

Ordered by how often our editor reaches for them.